DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main Sells 6,732 Shares of OraSure Technologies, Inc. (NASDAQ:OSUR)

DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lessened its holdings in OraSure Technologies, Inc. (NASDAQ:OSUR) by 3.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 219,648 shares of the medical instruments supplier’s stock after selling 6,732 shares during the quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main’s holdings in OraSure Technologies were worth $793,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Renaissance Technologies LLC raised its stake in OraSure Technologies by 23.1% in the 4th quarter. Renaissance Technologies LLC now owns 2,774,443 shares of the medical instruments supplier’s stock worth $10,016,000 after purchasing an additional 521,400 shares in the last quarter. Archon Capital Management LLC increased its holdings in shares of OraSure Technologies by 145.1% during the fourth quarter. Archon Capital Management LLC now owns 827,777 shares of the medical instruments supplier’s stock worth $2,988,000 after purchasing an additional 490,034 shares during the period. Peapod Lane Capital LLC bought a new position in shares of OraSure Technologies during the fourth quarter worth approximately $1,730,000. American Century Companies Inc. raised its position in shares of OraSure Technologies by 11.4% in the fourth quarter. American Century Companies Inc. now owns 2,345,837 shares of the medical instruments supplier’s stock valued at $8,468,000 after buying an additional 240,224 shares in the last quarter. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of OraSure Technologies in the fourth quarter valued at approximately $664,000. Institutional investors own 93.50% of the company’s stock.

OraSure Technologies Stock Down 3.5%

OSUR stock opened at $2.51 on Monday. OraSure Technologies, Inc. has a 52 week low of $2.42 and a 52 week high of $5.55. The business has a 50-day simple moving average of $3.16 and a 200 day simple moving average of $3.61. The company has a market cap of $194.49 million, a PE ratio of 16.73 and a beta of 0.42.

OraSure Technologies declared that its Board of Directors has initiated a stock buyback plan on Monday, March 24th that allows the company to repurchase $40.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 15.6% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its stock is undervalued.

Insiders Place Their Bets

In other news, CFO Kenneth J. Mcgrath acquired 64,000 shares of the stock in a transaction on Thursday, February 27th. The stock was acquired at an average cost of $3.15 per share, for a total transaction of $201,600.00. Following the completion of the transaction, the chief financial officer now directly owns 371,013 shares in the company, valued at approximately $1,168,690.95. This trade represents a 20.85% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John P. Kenny bought 47,659 shares of the business’s stock in a transaction on Thursday, February 27th. The shares were acquired at an average price of $3.17 per share, with a total value of $151,079.03. Following the completion of the purchase, the director now directly owns 70,915 shares of the company’s stock, valued at approximately $224,800.55. The trade was a 204.93% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 190,284 shares of company stock worth $600,348 over the last ninety days. Corporate insiders own 3.90% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com downgraded OraSure Technologies from a “hold” rating to a “sell” rating in a research report on Friday.

OraSure Technologies Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.